文献速递脊柱脊髓外科神经肿瘤

起源于脊髓的菊形团形成性胶质神经元肿瘤:2例报告及文献复习

Rosette-Forming Glioneuronal Tumor Originating From the Spinal Cord: Report of 2 Cases and Literature Review.
PubMed 文献 · World Neurosurg · 2016-11-30

报告2例起源于脊髓的菊形团形成性胶质神经元肿瘤(RGNT),术前分别误诊为室管膜瘤和星形细胞瘤。两例均行椎板切除全切术,病理确诊RGNT,未行放化疗,随访预后良好。作者认为手术是RGNT首选治疗,除侵袭性或复发性肿瘤外不推荐辅助放化疗。

要点

  • 脊髓RGNT极罕见,术前易误诊为室管膜瘤或星形细胞瘤。
  • 作者认为手术是RGNT首选治疗,不推荐对非侵袭性、非复发性肿瘤行辅助放化疗。
  • 作者建议进一步检查和常规随访以评估长期预后。

核心结论

  • 脊髓RGNT虽罕见但术前鉴别诊断重要,作者认为手术是首选治疗,除侵袭性或复发性肿瘤外不推荐辅助放疗和化疗,并建议进一步检查和常规随访以评估长期预后。

研究设计与样本

  • 病例报告2例及文献复习,报告起源于脊髓的RGNT 2例,术前分别误诊为室管膜瘤和星形细胞瘤。
  • 对2例肿瘤行端粒酶逆转录酶启动子、异柠檬酸脱氢酶1/2、BRAF-V600E和O(6)-甲基鸟嘌呤-DNA甲基转移酶启动子等基因突变分析。

主要发现

  • 病例1表现为分离性感觉障碍及间断性疼痛和乏力2年,病例2表现为运动障碍2个月。
  • MRI显示肿块位于胸腰段(T7-L1)和颈胸段(C3-C7)脊髓,实性部分T1加权像呈低信号、T2加权像呈高信号,钆增强后呈不均匀强化。
  • 两例均经正中椎板切除行全切术,术后病理确诊RGNT,未行放疗或化疗,末次随访两例预后均良好。

临床怎么用

  • 作者认为手术是RGNT的首选治疗。
  • 作者不推荐对侵袭性或复发性肿瘤以外的RGNT患者实施辅助放疗和化疗。
  • 作者建议进一步检查和常规随访以评估长期预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rosette-forming glioneuronal tumor (RGNT) is a recently recognized and rarely encountered tumor occurring in the fourth ventricle. RGNT was first described as a new entity for the distinct clinicopathologic features by Komori et.al. in 2002. Histologically, it is composed of 2 distinct features: a glial component, resembling pilocytic astrocytoma, and a neurocytic component forming neurocytic rosettes and/or perivascular rosettes. We report 2 extremely rare cases of RGNT arising from the spinal cord, which were misdiagnosed as ependymoma and astrocytoma preoperatively. Symptoms included dissociated sensory disturbances and episodic pain and fatigue of 2 years' duration in case 1, as well as motor disturbance for 2 months' duration in case 2. Magnetic resonance imaging (MRI) revealed these masses in the thoracolumbar (T7-L1) and cervicothoracic (C3-C7) spinal cord. The solid component appeared hypointense in T1-weighted MRI sequences, hyperintense in the T2-weighted MRI sequences, and heterogeneous in MRI images enhanced with gadolinium contrast medium in both cases. Gross total resection was performed via a median laminectomy. Postoperative pathological examination confirmed the diagnosis of RGNT. In addition, extensive analysis of genetic mutations was performed to explore the relationship with glioma, including telomerase reverse transcriptase promoter, isocitrate dehydrogenase 1/2, BRAF-V600E, and O(6)-methylguanine-DNA methyltransferase promoter. No radiotherapy or chemotherapy were performed in these two cases. As of the latest follow-up, both patients had a good prognosis. Given the widely varying clinical characteristics of, prognosis of, and treatments for spinal tumors, differential diagnosis is of great importance before surgery. Consideration of the tumor location and the patient's age and sex, in combination with the imaging features, may be the best approach to narrowing the differential diagnosis. Surgery is the preferred treatment for RGNT. We do not recommend to implement adjuvant radiotherapy and chemotherapy in these patients except the invasive or recurrent tumors. Further examination and routine follow-up should be recommended to estimate the long-term prognosis.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Duan L, Zhang Y, Fu W, et al. Rosette-Forming Glioneuronal Tumor Originating From the Spinal Cord: Report of 2 Cases and Literature Review. World Neurosurg. 2016. PMID: 27915062. doi:10.1016/j.wneu.2016.11.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。